• Researcher Profile

    F. Stephen Hodi, Jr., MD

     
    F. Stephen Hodi, Jr., MD

    Top Doctor

     
    Director, Melanoma Center
    Director, Center for Immuno-Oncology


    Associate Professor of Medicine, Harvard Medical School

    Center/Program

    Melanoma

    Office phone: 617-632-5055
    Fax: 617-632-6727
    Website: Patient Gateway

    Preferred contact method: office phone

    View Physician Profile
     
     

    Research Department

    Medical Oncology/Solid Tumor Oncology

    Interests

    Gene therapy for cancer, Melanoma, Tumor immunology

    Area of Research

    Combination Immunotherapies for Cancer

    Dana-Farber Cancer Institute
    450 Brookline Avenue
    Dana 540
    Boston, MA 02215

    Biography

    Dr. Hodi is the Director of the Melanoma Center and the Center for Immuno-Oncology at Dana-Farber/Brigham and Women's Cancer Center and Assistant Professor of Medicine at Harvard Medical School. He received his MD degree from Cornell University Medical College in 1992. Dr. Hodi competed his postdoctoral training in Internal Medicine at the Hospital of the University of Pennsylvania, and Medical Oncology training at Dana-Farber cancer Institute where he joined the faculty in 1995. His research focuses on gene therapy, the development of immune therapies, and first into human studies for malignant melanoma. Dr. Hodi is a member of the National Comprehensive Cancer Network, the American Society of Clinical Oncology, the Eastern Cooperative Oncology Group Melanoma Committee, the International Society for the Biological Therapy of cancer, and a founding member of the Society for Melanoma Research.

    Recent Awards

    • Mentoring Clinical Scientist Development Award, 1998

    Research

    Combination Immunotherapies for Cancer

    The ability to manipulate genes that encode potential immunomodulators, such as cytokines and tumor antigens, has opened a new era of research. Poorly immunogenic murine tumor systems demonstrate that vaccination with irradiated tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor (GM-CSF) generates potent, specific, and long-lasting immunity.

    To test this strategy in patients with advanced melanoma, our laboratory performed a clinical trial of vaccination with lethally irradiated, autologous melanoma cells expressing human GM-CSF. Vaccination elicited a striking infiltrate of large numbers of lymphocytes, plasma cells, macrophages, and eosinophils, resulting in tumor destruction, fibrosis, and edema. These results provide a solid foundation for undertaking a molecular analysis of the melanoma antigens stimulating specific T and B cell responses in vaccinated patients. Candidate antigens are identified from screening with autologous sera of a complementary DNA expression library constructed from vaccinated patients' tumor cell lines. For a number of antigens evaluated, potent humoral immune responses are associated with immune-mediated destruction of diverse tumors - offering the promise of future antigen-directed therapies.

    One mechanism that may limit the therapeutic potency of cancer vaccines is the attenuation of T cell function by cytotoxic T lymphocyte-associated antigen 4 (CTLA-4). Striking therapeutic synergies have been observed between CTLA-4 blockade and GM-CSF-secreting tumor cell vaccines in murine models of melanoma, breast cancer, and prostate cancer. Based on these preclinical data, we initiated a phase I clinical trial of single administration of anti-CTLA-4 antibody (MDX-CTLA-4) in previously vaccinated patients with metastatic melanoma or ovarian cancer. Of the nine subjects treated, three had received irradiated, autologous GM-CSF-secreting melanoma cells; four patients with metastatic melanoma had received vaccinations against melanosomal antigens; and two patients with ovarian cancer had received autologous GM-CSF-secreting cells.

    The three patients who received autologous GM-CSF-secreting melanoma cell vaccines demonstrated extensive tumor necrosis associated with hemorrhage and immune infiltrates in response to MDX-CTLA-4. In contrast, four of four patients who received vaccinations for melanosomal antigens failed to develop an immune infiltrate or tumor necrosis in response to MDX-CTLA4. The two patients with ovarian cancer had either a decrease or plateau to their CA-125 tumor marker levels following treatment with MDX-CTLA-4.

    The immune infiltrates and massive tumor destruction witnessed in patients who had received MDX-CTLA-4 and GM-CSF-secreting cell vaccines suggest synergistic antitumor effects. This work provides the basis for additional studies to verify these observations in additional tumor types and to test combination immunotherapy modalities.

    Select Publications

    • Schmollinger JC, Vonderheide RH, Hoar KM, Maecker B, Schultze JL, Hodi FS, Soiffer RJ, Jung K, Kuroda MJ, Letvin NL, Greenfield EA, North PE, Mihm M, Kutok JL, Dranoff G. The inhibitor of apoptosis protein ML-IAP is a target for immune mediated tumor destruction. Proc Natl Acad Sci U S A 2003;100:3398-403.
    • Mollick JA, Hodi FS, Soiffer R, Nadler LM, Dranoff G. MUC1-like tandem repeat proteins are broadly immunogenic in cancer patients. Cancer Immun 2003;3:3.
    • Salgia R, Lynch T, Skarin A, Lucca J, Lynch C, Jung K, Hodi FS, Jaklitsch M, Mentzer S, Swanson S, Lukanich J, Bueno R, Wain J, Mathiesen D, Wright C, Fidias P, Donahue D, Clift S, Hardy S, Neuberg D, Mulligan R, Webb I, Sugarbaker D, Mihm M, Dranoff G. Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in patients with metastatic non-small cell lung carcinoma. J Clin Oncol 2003;21:624-30.
    • Katz KA, Jonasch E, Hodi FS, Soiffer R, Kwitkiwski K, Sober AJ, Haluska FG. Melanoma of unknown primary: experience at Massachusetts General Hospital and Dana-Farber Cancer Institute. Melanoma Res 2005;15:77-82.
    • Soiffer R, Hodi FS, Haluska F, Jung K, Gillessen S, Singer S, Tanabe K, Duda R, Mentzer S, Jaklitsch M, Bueno R, Clift S, Hardy S, Neuberg D, Mulligan R, Webb I, Mihm M, Dranoff G. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J Clin Oncol 2003;21:3343-50.
    • Hodi FS, Mihm MC, Soiffer RJ, Haluska FG, Butler M, Seiden M, Davis T, Henry-Spires R, MacRae S, Willman A, Padera R, Jaklitsch MT, Shankar S, Chen TC, Korman A, Allison JP, Dranoff G. Biologic activity of CTLA-4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A 2003;100:4712-7.
View Physician Directory

Find a Clinical Trial

Support Cancer
Research

Give Now